Celltrion Completes Gifrer Integration in France
Celltrion has completed the post-acquisition integration of French healthcare company Gifrer and is set to launch full-scale pharmacy sales network operations aimed at expanding its presence in the European market.Celltrion Group Chairman Seo Jeong-jin personally visited the company’s French subsidi
Celltrion has finalized the integration of French healthcare firm Gifrer, positioning itself for a substantial pharmacy sales network expansion across Europe. Celltrion Group Chairman Seo Jeong-jin personally inspected the newly combined operations in France, emphasizing the need to accelerate execution and replicate the successful French model throughout the continent.
Post-integration, Celltrion now commands a pharmacy sales network of about 9,000 outlets and a hospital supply chain serving approximately 800 facilities. Gifrer's portfolio of around 140 over-the-counter drugs and health functional foods, when combined with Celltrion's direct biopharmaceutical sales, creates a comprehensive hospital-to-pharmacy sales network, crucial for subcutaneous drug distribution.
France's pharmacy substitution dispensing regulations, introduced in 2022, are driving up the range of eligible products, and Celltrion aims to capitalize on this by potentially launching direct pharmacy sales of its bone disease treatment Stoboclo-Osenvelt. The company is pursuing a diversification strategy, exploring the licensing-in of third-party biosimilars or generic products with high pharmacy demand to enhance sales efficiency and revenue.
Celltrion intends to use France as a pilot for its European pharmacy direct-sales model, with plans to expand to other Western European countries with strong direct-sales foundations.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
